Ocugen will continue second phase of OCU410 ArMaDa clinical trial

News
Article

The potential gene therapy candidate is being evaluated for geographic atrophy.

Solution being administered into test tubes Image credit: AdobeStock/AerialMike

Image credit: AdobeStock/AerialMike

The Data and Safety Monitoring Board (DSMB) for the OCU410 ArMaDa clinical trial convened and approved continuation of the second phase of the Phase 1/2 study. The candidate being evaluated, OCU410 (AAV5-hRORA), is a novel modifier gene therapy candidate being developed for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

Peter Chang, MD, FACS, Co-President and Partner of the Massachusetts Eye Research and Surgery Institution (MERSI) spoke to the information the board took into account, saying, “The DSMB assessed data on 15 subjects from Phase 2. Initial data indicates that OCU410 appears to be safe and well-tolerated. No serious adverse events (SAEs) related to OCU410 have been reported to date.”1

According to the company’s press release,1 the ArMaDa clinical trial is set to assess the safety and efficacy of unilateral subretinal administration of OCU410 in subjects with GA. Phase 2 is an ongoing, randomized, outcome assessor-blinded, dose-expansion study in which 45 subjects are randomized in a 1:1:1 ratio to either one of two OCU410 treatment groups (5×1010 vg/mL or 1.5 ×1011 vg/mL) or an untreated control group.

Huma Qamar, MD, MPH, CMI, Chief Medical Officer of Ocugen noted that this potential treatment may decrease the treatment burden associated with AMD, saying, “Currently approved treatments for GA require 6-12 intravitreal injections annually and frequent injections are a burden on patients and caregivers. We are very enthusiastic about the potential of OCU410 to serve as a game-changing, one-time treatment for life for patients with GA.”1

Positive preliminary efficacy and safety data from the Phase 1 dose-escalation portion of the ArMaDa clinical trial demonstrated: no drug-related serious adverse events, reduced lesion growth, preservation of retinal tissue, and—most importantly—there was a positive effect on the functional visual measure of low luminance visual acuity (LLVA).1

The ArMaDa clinical trial is currently being performed at 13 leading retinal surgery centers across the U.S. Dosing in the OCU410 ArMaDa clinical trial will be completed in early 2025 and the Company will continue to provide 9- and 12-month efficacy updates from Phase 1.1

Reference:
  1. Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. Ocugen. December 19, 2024. Accessed January 2, 2025. https://www.globenewswire.com/news-release/2024/12/19/2999700/0/en/Data-and-Safety-Monitoring-Board-Reviews-Interim-Safety-Data-of-Phase-2-Subjects-of-OCU410-ArMaDa-Clinical-Trial-for-Geographic-Atrophy-Secondary-to-Dry-Age-Related-Macular-Degener.html

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
Steven Greenstein, MD, one of the cochairs of the Collaborative Care Symposium gave some insight into the upcoming conference and what attendees can expect.
Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
© 2025 MJH Life Sciences

All rights reserved.